as on March 11, 2026 at 6:59 am IST
Day's Low
Day's High
1.39%
Downside
0.64%
Upside
52 Week's Low
52 Week's High
38.40%
Downside
26.63%
Upside
Check Genmab A/s market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$16.7B
EPS (TTM)
1.0934
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
-0.94%
PE Ratio (TTM)
17.69
Industry PE ratio
17.50525641025641
PEG Ratio
1.7494
EBITDA
1.3B
Revenue (TTM)
3.7B
Profit Margin
25.89%
Return On Equity TTM
17.54%
Track how Genmab A/s P/E has moved over time to understand its valuation trends.
Genmab A/s in the last 5 years
Lowest (4.63x)
March 31, 2021
Industry (17.51x)
March 11, 2026
Today (17.69x)
March 11, 2026
Highest (64.13x)
September 30, 2021
Today’s Price to Earnings Ratio: 17.69x
Compare market cap, revenue, PE, and other key metrics of Genmab A/s with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $16.7B | -15.53% | 17.69 | 25.89% | |
| BUY | $42.9B | 125.47% | 138.88 | 8.45% | |
| BUY | $117.1B | 132.01% | 30.12 | 32.94% | |
| NA | $34.9B | NA | 121.89 | 5.37% | |
| BUY | $82.6B | 64.28% | 18.83 | 31.41% |
The Genmab A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Genmab A/s investment value today
Current value as on today
₹1,43,297
Returns
₹43,297
(+43.3%)
Returns from Genmab A/s Stock
₹38,105 (+38.1%)
Dollar Returns*
₹5,192 (+5.19%)
Based on 31 analysts
61.29%
Buy
29.03%
Hold
9.68%
Sell
Based on 31 analysts, 61.29% of analysts recommend a 'BUY' rating for Genmab A/s. Average target price of $37.65
Get share price movements and forecasts by analysts on Genmab A/s.
What analysts predicted
25.68%UPSIDE
Target Price
$37.65
Current Price
$27.98
Analyzed by
31 Analysts
Target
$37.65
Genmab A/s target price $37.65, a slight upside of 25.68% compared to current price of $27.98. According to 31 analysts rating.
Search interest for Genmab A/s Stock has decreased by -22% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 17 February
Tue, 09:32 PM
-Genmab publishes 2025 Annual Report, highlighting revenue growth and key product approvals.
Wed, 00:16 AM
-Genmab reports Q4 earnings, with 19% revenue growth and significant proprietary medicine sales increase.
Wed, 01:45 AM
-Genmab initiates share buy-back program, repurchasing up to 342,130 shares for 725 million DKK.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
![]()
Revenue is up for the last 2 quarters, 1.02B → 6.72B (in $), with an average increase of 84.8% per quarter
Against Peers
![]()
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 77.2% return, outperforming this stock by 99.1%
Against Peers
![]()
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 1.0%
Profit Down
![]()
Netprofit is down for the last 3 quarters, 2.12B → 196.98M (in $), with an average decrease of 66.0% per quarter
Price Dip
![]()
In the last 1 month, GMAB stock has moved down by -9.4%
| Organisation | Genmab A/s |
| Headquarters | Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500 |
| Industry | Health Technology |
| CEO | Dr. Jan G.J. van de Winkel Ph.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Dr. Mijke Zachariasse Ph.D. | VP, Head of Antibody Research Materials & Director |
Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO |
Mr. Christopher Cozic | Executive VP & Chief People Officer |
Dr. Judith V. Klimovsky M.D. | Executive VP & Chief Development Officer |
Dr. Martine J. van Vugt Ph.D. | Executive VP & Chief Strategy Officer |
Mr. Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director |
Dr. Tahamtan Ahmadi M.D., Ph.D. | Executive VP, Chief Medical Officer & Head of Experimental Medicines |
Mr. Anthony Pagano CPA | Executive VP & CFO |
Mr. Rayne Waller | Executive VP & Chief Technical Operations Officer |
Mr. Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer |
Genmab A/s share price today is $27.98 as on at the close of the market. Genmab A/s share today touched a day high of $28.16 and a low of $27.59.
Genmab A/s share touched a 52 week high of $35.43 on and a 52 week low of $17.24 on . Genmab A/s stock price today i.e. is closed at $27.98,which is 21.03% down from its 52 week high and 62.34% up from its 52 week low.
Genmab A/s market capitalisation is $0.02T as on .
Indian investors can start investing in Genmab A/s (GMAB) shares with as little as ₹91.833 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹918.33 in Genmab A/s stock (as per the Rupee-Dollar exchange rate as on ).
Based on Genmab A/s share’s latest price of $27.98 as on March 11, 2026 at 1:29 am IST, you will get 0.3574 shares of Genmab A/s. Learn more about
fractional shares .
Genmab A/s stock has given -15.53% share price returns and 26.32% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?